200,000 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Acquired by Rock Springs Capital Management LP

Rock Springs Capital Management LP bought a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 200,000 shares of the medical technology company's stock, valued at approximately $1,836,000. Rock Springs Capital Management LP owned approximately 0.14% of Alphatec as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in shares of Alphatec by 99.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,948 shares of the medical technology company's stock valued at $165,000 after purchasing an additional 8,929 shares during the period. MetLife Investment Management LLC increased its stake in Alphatec by 6.2% during the 4th quarter. MetLife Investment Management LLC now owns 63,274 shares of the medical technology company's stock worth $581,000 after buying an additional 3,719 shares during the period. Altium Capital Management LLC acquired a new position in Alphatec in the 4th quarter worth $2,429,000. Marshall Wace LLP lifted its holdings in Alphatec by 139.2% in the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock worth $16,278,000 after buying an additional 1,032,070 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in Alphatec by 116.1% in the 4th quarter. XTX Topco Ltd now owns 26,746 shares of the medical technology company's stock valued at $246,000 after buying an additional 14,368 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP David Sponsel sold 36,256 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the transaction, the executive vice president now owns 735,074 shares of the company's stock, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Patrick Miles sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the completion of the sale, the chief executive officer now directly owns 6,152,544 shares of the company's stock, valued at approximately $74,015,104.32. This represents a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 272,113 shares of company stock worth $3,121,225. 22.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ATEC shares. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Thursday, February 27th. Piper Sandler increased their target price on Alphatec from $12.00 to $13.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.67.

Alphatec Stock Performance

NASDAQ ATEC traded up $0.11 during trading hours on Friday, reaching $11.51. The company's stock had a trading volume of 1,056,380 shares, compared to its average volume of 2,048,584. The stock has a market cap of $1.66 billion, a PE ratio of -8.99 and a beta of 1.20. The business has a 50-day simple moving average of $10.40 and a 200 day simple moving average of $9.65. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $13.79. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.